CMAJ • April 27, 2004; 170 (9). doi:10.1503/cmaj.1020049.
© 2004 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fazio, L.
Right arrow Articles by Brock, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fazio, L.
Right arrow Articles by Brock, G.
Related Collections
Right arrow Urology
Right arrow Erectile dysfunction

Review
Synthèse

Erectile dysfunction: management update

Luke Fazio and Gerald Brock

From the Division of Urology, Faculty of Medicine and Dentistry, University of Western Ontario, London, Ont.

Abstract

DRAMATIC ADVANCES IN THE MANAGEMENT of erectile dysfunction have occurred over the past decade. Oral therapy with vasoactive agents has emerged as first-line treatment and has transformed both the manner in which the public views erectile dysfunction and the way health care providers deliver care. Whereas an extensive investigation was previously common in the management of erectile dysfunction, recent treatment guidelines promote a more minimalist, goal-oriented approach. In this article, we review the physiology of erection, and the pathophysiology, diagnosis and clinical management of erectile dysfunction. We also present the existing evidence for the efficacy of 3 phosphodiesterase inhibitors, the most widely used class of agents for erectile dysfunction.




This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
A. Tsertsvadze, H. A. Fink, F. Yazdi, R. MacDonald, A. J. Bella, M. T. Ansari, C. Garritty, K. Soares-Weiser, R. Daniel, M. Sampson, et al.
Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis
Ann Intern Med, November 3, 2009; 151(9): 650 - 661.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
A. Tsertsvadze, H. A. Fink, F. Yazdi, R. MacDonald, A. J. Bella, M. T. Ansari, C. Garritty, K. Soares-Weiser, R. Daniel, M. Sampson, et al.
Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis
Ann Intern Med, October 19, 2009; (2009) 0000605-200911030-00150v1.
[Abstract] [Full Text]

Home page
 CMAJHome page
E. Wooltorton
Visual loss with erectile dysfunction medications
Can. Med. Assoc. J., August 15, 2006; 175(4): 355 - 355.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. E. Teixeira, F. B. M. Priviero, and R. C. Webb
Differential Effects of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Vardenafil, and Tadalafil in Rat Aorta
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 654 - 661.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. M Setter, J. L Iltz, J. E Fincham, R K. Campbell, and D. E Baker
Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
Ann. Pharmacother., July 1, 2005; 39(7): 1286 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
B. Danby
Does testosterone affect effect?
Can. Med. Assoc. J., September 14, 2004; 171(6): 553 - 553.
[Full Text] [PDF]

Home page
 CMAJHome page
G. Brock
Does testosterone affect effect?
Can. Med. Assoc. J., September 14, 2004; 171(6): 553 - 553.
[Full Text] [PDF]

eLetters:

Read all eLetters

Does testosterone affect effect?
Bill Danby
CMAJ, 5 May 2004 [Full text]